



Gastrointestinal (GI) Disease-Oriented Team

Clinical Research Treatment Trial Flowchart





UCI 25-149

(Metformin use for Pseudomyxoma
Peritonei secondary to appendiceal
mucinous neoplasms)

Coord: C. Jonsson

PI: Dr. Eng

Accrual: 0/15

Newly Diagnosed

Advanced/Metastatic

Neoadjuvant	Newly Diagnosed Metastatic	Recurrent
<u>UCI 21-191</u> (SOC w/ ctDNA testing) (opened 6/27/25) Coord: A. Ballard PI: Dr. Dayyani Accrual: 14/20	<u>A022102</u> (mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab) Coord: C. Jonsson PI: Dr. Dayyani Accrual: 9/14	<u>UCI 16-94</u> (Tirapazamine + Nivolumab) Coord: S. Duong PI: Dr. Abi-Jaoudeh Accrual: 40/48
<u>UCI 23-184</u> (Pafolacianine for Imaging of Peritoneal Carcinomatosis) Coord: L. Mejia PI: Dr. Senthil Accrual: 10/10	<u>UCI 21-10</u> (FOLFOX + nivo + TJ033721 (anti-CLDN18.2 + anti-4-1BB) Coord: M. Nguyen; C. Jonsson PI: Dr. Dayyani Accrual: 37/50	<u>UCI 24-49</u> (Zongertinib + Trastuzumab + Deruxetecan or + Trastuzumab Emtansine) Coord: M. Nguyen PI: Dr. Dayyani Accrual: 3/10
ESCC	Newly Diagnosed Non-Metastatic	
<u>UCI 24-77</u> (I-DXd) (opened 2/5/26) Coord: C. Jonsson PI: Dr. Dayyani Accrual: 0/5	<u>UCI 23-173</u> (Tremelimumab and Durvalumab in ARID1 mutated) (opened 5/29/26) PI: Dr. Dayyani Accrual: 0/34	
	<u>UCI 26-78</u> (Sonesitaturg Vedotin + Capecitabine +/- Rilvegostomig) Coord: TBD PI: Dr. Dayyani <u>Pending activation</u>	<u>UCI 26-60</u> (ASP546C) Coord: TBD PI: Dr. Dayyani <u>Pending activation</u>

HER-2	KRAS	EGFR	CLDN18.2
<u>UCI 24-49</u> (Beamion BCGC-1: Oral Zongertinib + Trastuzumab Deruxtecen) (opened 10/22/24) Coord: M. Nguyen PI: Dr. Dayyani Accrual: 3/10	<u>UCI 25-163</u> (BBO-11818) Coord: N. Ferrand PI: Dr. Arter Accrual: 0/5		<u>UCI 21-10</u> (FOLFOX + nivo + TJ033721 (anti- CLDN 18.2 + anti-4-1BB) Coord: M. Nguyen/C. Jonsson PI: Dr. Dayyani Accrual: 37/50
			<u>UCI 26-78</u> (Sonesitatug Vedotin + Capecitabine +/- Rilvegostomig) Coord: TBD PI: Dr. Dayyani <u>Pending activation</u>
			<u>UCI 26-60</u> (ASP546C) Coord: TBD PI: Dr. Dayyani <u>Pending activation</u>

UCI 23-85 (BA3182 + (EPCAM/CD3 AB) (opened 9/19/24) Coord: P. Yang PI: Dr. Valerin Accrual: 8/18	ETCTN-10572 (Temozolomide + M1774) (opened 12/11/2025) Coord: M. Nguyen PI: Dr. Dayyani Accrual: 2/10	ETCTN-10579 (ZEN-3694) + capecitabine) (opened 10/27/23) Coord: P. Yang PI: Dr. FC Lee Accrual: 2/4
UCI 24-113 (BMS-986482 +/- immunotherapy) (opened 9/29/2025) Coord: L. Mejia PI: Dr. Chow Accrual: 5/10	UCI 21-241 (ALK inhibitor NLV-655) (opened 10/4/22) Coord: A. Ballard PI: Dr. Nagasaka Accrual: 20/25	UCI 25-190 (STOPGAP-B) (IP Paclitaxel + SOC in GI Malignancies with Peritoneal Carcinomatosis) (opened 7/31/26) Coord: TBD PI: Dr. Senthil Accrual: 0/45
UCI 25-16 (ODM-212) (opened 8/29/2025) Coord: P. Yang PI: Dr. Dayyani Accrual: 11/20	UCI 25-75 (CRN09682- on SST2 tumors) (opened 2/18/2026) Coord: S. Duong PI: Dr. Dayyani Accrual: 0/15	UCI 25-181 (TAK505) Coord: TBD PI: Dr. Dayyani <u>Pending activation</u>



UCI 03-03
(Immunologic response analysis)

Coord: B. Sanchez
PI: Dr. Imagawa
Accrual: 336/400

UCI 22-55
(Early Detection and Diagnosis
of DNA Repair Deficient
Hereditary Cancers)

(opened 3/13/2025)
PI: Dr. Pannunzio/Dr. Valerin
Accrual: 16/50

UCI 24-05
(Riluzole for Cancer- related
Cognitive Impairment)

Coord: M. Nguyen
PI: Dr. Chan
Accrual: 30/59

UCI 25-48
(Riluzole For Preventing
Cognitive Dysfunction in
Pts Receiving Chemo)

Coord: M. Nguyen
PI: Dr. Chan
Accrual: 12/20